Elanco Animal Health (NYSE:ELAN) Releases FY 2025 Earnings Guidance

Key Points

• Elanco Animal Health has provided its FY 2025 earnings guidance, projecting earnings per share between $0.850 and $0.910, which exceeds the consensus estimate of $0.840.
• The company's revenue guidance for FY 2025 is set at $4.6 billion, surpassing the consensus estimate of $4.5 billion.
• Analysts have updated their ratings for Elanco, with several upgrading the stock to "buy" or "outperform," leading to a consensus price target of $16.17.

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.850-0.91 for the period, compared to the consensus earnings per share estimate of 0.840. The company issued revenue guidance of $4.6 billion-$4.6 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its Q3 2025 guidance to 0.120-0.160 EPS.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $14.03 on Thursday. The firm has a market capitalization of $6.97 billion, a P/E ratio of 18.96, a P/E/G ratio of 2.76 and a beta of 1.66. The stock has a fifty day moving average price of $14.20 and a two-hundred day moving average price of $12.02. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $15.78. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. As a group, analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a report on Thursday, July 17th. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Finally, Stifel Nicolaus lifted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.17.

Institutional Trading of Elanco Animal Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Empowered Funds LLC raised its position in shares of Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock valued at $166,000 after buying an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock valued at $18,830,000 after purchasing an additional 76,408 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Elanco Animal Health in the 1st quarter valued at $2,065,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.